NCT04587622View on ClinicalTrials.gov

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions
Hepatic Failure
Interventions
DRUG

Icenticaftor

Single oral dose of 300 mg of icenticaftor (QBW251)

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

33014-3616

Novartis Investigative Site, Miami

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY